In CD19 CAR-T therapy, it is generally accepted to use a combination of CD19 with CD22, BCMA, and CD20.147 A bispecific CAR-T (CD19–22.BB.z-CAR) dual-targeting CD19 and CD22 was investigated in a phase I study for patients with large B cell lymphoma (LBCL) and relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL). Here, CD19 is linked to acute lymphoblastic leukemia.